COVIS
PharmaCOVIS is a pharmaceutical company focused on Respiratory.
COVIS's Key Drugs
COVIS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
COVIS's Recent FDA Approvals
New NDA/BLA approvals for COVIS over the last two years — novel drugs only, excluding generics and label supplements.
COVIS's Therapeutic Areas
COVIS's approved drugs and pipeline span 1 therapeutic area, led by Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
COVIS's Top Competitors
COVIS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
COVIS Pipeline Snapshot
Active clinical trials for COVIS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2008-01-10
- Latest
- 2023-02-16
- Applications
- 1